[1. Gaieski, David, Edwards, Kallan, Michael, Carr, Brendan, MD, MA. Benchmarking the Incidence and Mortality of Severe Sepsis in the United States*. Crit Care Med. 2013; 41(5):1167-1174. doi: 10.1097/CCM.0b013 e31827c09f8.]Search in Google Scholar
[2. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med 2016; 193(3): 259-72.10.1164/rccm.201504-0781OC26414292]Search in Google Scholar
[3. Stevenson EK, et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2014;42(3):625–3110.1097/CCM.0000000000000026431393024201173]Search in Google Scholar
[4. Lagu T, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012;40(3):754–6110.1097/CCM.0b013e318232db6521963582]Search in Google Scholar
[5. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence 2014; 5(1):4–1110.4161/viru.27372391638224335434]Search in Google Scholar
[6. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801–1010.1001/jama.2016.0287496857426903338]Search in Google Scholar
[7. Dogaru, S., Teusdea, C., & Purcaru, F. (2020). Risk Stratification in Sepsis: What We Can Do in the Emergency Room?, Internal Medicine, 17(3), 37-42. doi: https://doi.org/10.2478/inmed-2020-011510.2478/inmed-2020-0115]Search in Google Scholar
[8. Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. London: RCP, 2017]Search in Google Scholar
[9. APA Shapiro, Nathan I. MD; Wolfe, Richard E. MD; Moore, Richard B. MD; Smith, Eric BA; Burdick, Elizabeth PhD; Bates, David W. MD, MSc Mortality in Emergency Department Sepsis (MEDS) score: A prospectively derived and validated clinical prediction rule*, Critical Care Medicine: March 2003 - Volume 31 - Issue 3 - p 670-675 doi: 10.1097/01.CCM.0000054867.01688.D110.1097/01.CCM.0000054867.01688.D112626967]Search in Google Scholar
[10. Bomberg H, Volk T, Groesdonk HV, et al. Presepsin (sCD14-ST) Is a Novel Marker for Risk Stratification in Cardiac Surgery Patients. Anesthesiology. 2017. doi:10.1097/ALN.000000000000152210.1097/ALN.000000000000152228099244]Search in Google Scholar
[11. Erenler AK, Yardan T. Presepsin (sCD14-ST) as a biomarker of sepsis in clinical practice and in emergency department: A mini review. LaboratoriumsMedizin. 2015. doi:10.1515/labmed-2015-007210.1515/labmed-2015-0072]Search in Google Scholar
[12. Behnes M, Lepiorz D, Lang S, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014. doi: 10.1186/s13054-014-0507-z10.1186/s13054-014-0507-z417428325190134]Search in Google Scholar
[13. Yang HS, Hur M, Yi A, Kim H, Lee S, Kim SN. Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis. PLoS One. 2018;13(1). doi:10.1371/journal.pone.019148610.1371/journal.pone.0191486578338029364941]Search in Google Scholar
[14. Marshall, J.C. The staging of sepsis: understanding heterogeneity in treatment efficacy. Crit Care 9, 626 (2005). https://doi.org/10.1186/cc390710.1186/cc3907141400916356249]Search in Google Scholar
[15. Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care. Am J Respir Crit Care Med. 2015; 192(9):1045-1051. doi:10.1164/rccm.201411-2125CP10.1164/rccm.201411-2125CP464219926177009]Search in Google Scholar